87th Legislative Session _ 2012

Committee: Senate Health and Human Services
Wednesday, January 25, 2012

                                            P - Present
                                            E - Excused
                                            A - Absent

Roll Call
P    Bradford
P    Holien
P    Krebs
P    Rampelberg
P    Schlekeway
P    Kraus, Vice-Chair
P    Hunhoff (Jean), Chair

OTHERS PRESENT: See Original Minutes

The meeting was called to order by Senator Jean Hunhoff, Chair.

MOTION:    TO APPROVE THE MINUTES OF MONDAY, JANUARY 23, 2012

Moved by:    Schlekeway
Second by:    Krebs
Action:    Prevailed by voice vote.

GAVEL PASSED TO SENATOR ELIZABETH KRAUS, VICE CHAIR

        SB 69: repeal the sunset provision on certain statutes relating to nursing homes on Indian reservations.

Presented by:    Senator Jim Bradford

MOTION:    DO PASS SB 69

Moved by:    Krebs
Second by:    Holien
Action:    Prevailed by roll call vote. (6-0-1-0)

Voting Yes:    Bradford, Holien, Krebs, Rampelberg, Schlekeway, Kraus

Excused:    Hunhoff (Jean)

RECESS FOR TEN MINUTES

        SB 72: regulate persons offering speech-language pathology to the public.

Presented by:    Senator Jean Hunhoff
Proponents:    Jennifer Shultz, Self, Freeman (Handouts: #1, #2)
        Greg Von Wald, Mitchell Technical Institute
        Penny McCormick Gilles, Self, Platte
Opponents:    Micky Hutchinsion, Self, Isabel (Teleconference)

MOTION:    DO PASS SB 72

Moved by:    Schlekeway
Second by:    Krebs
Action:    Prevailed by roll call vote. (7-0-0-0)

Voting Yes:    Bradford, Holien, Krebs, Rampelberg, Schlekeway, Kraus, Hunhoff (Jean)

GAVEL PASSED BACK TO SENATOR JEAN HUNHOFF, CHAIR

MOTION:    TO INTRODUCE AT THE REQUEST OF THE GOVERNOR THE FOLLOWING BILL: AN ACT TO ESTABLISH A PROGRAM TO ASSIST RURAL HEALTH CARE FACILITIES IN RECRUITING CERTAIN HEALTH CARE PROFESSIONALS AND TO REPEAL CERTAIN PROVISIONS REGARDING RECRUITMENT INCENTIVE PAYMENTS FOR HEALTH CARE PROFESSIONALS.

Moved by:    Kraus
Second by:    Krebs
Action:    Prevailed by voice vote.

MOTION:    TO INTRODUCE AT THE REQUEST OF THE GOVERNOR THE FOLLOWING BILL: AN ACT TO ESTABLISH A PROGRAM TO ASSIST RURAL COMMUNITIES TO RECRUIT CERTAIN HEALTH CARE PROFESSIONALS AND TO REPEAL CERTAIN PROVISIONS REGARDING THE PHYSICIAN AND THE DENTIST TUITION REIMBURSEMENT PROGRAMS.

Moved by:    Kraus
Second by:    Rampelberg
Action:    Prevailed by voice vote.

SB23 CONTINUED FROM MONDAY, JANUARY 23, 2012 MEETING.

        SB 23: place certain substances on the controlled substances schedule and to declare an emergency.

Opponents:    N. Bob Pesall, Self, Flandreau

MOTION:    AMEND SB 23

23ja

    On page 3, line 9, of the printed bill, after "Cathinone" insert "and other variations, defined as any compound, material, mixture, preparation or other product unless listed in another schedule or an approved FDA drug (e.g. buproprion, pyrovalerone), structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:

            (a)    By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substitutents;

            (b)    By substitution at the 3-position with an acyclic alkyl substituent;

            (c)    by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

                Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone); 3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone); 3,4-methylenedioxyethcathinone (ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone (metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP); 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP);

Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4'-Methyl-?-pyrrolidinobutiophenone (MPBP)".


    On page 3, line 10, overstrike everything after "(38)" .

    On page 3, line 11, overstrike "(39)".

    On page 3, line 12, overstrike "(40)" and insert "(39)".

    On page 3, line 13, overstrike "(41)" and insert "(40)".

    On page 3, line 14, overstrike "(42)" and insert "(41)".

    On page 3, line 15, overstrike "(43)" and insert "(42)".

    On page 3, line 16, overstrike "(44)" and insert "(43)".

    On page 3, line 17, overstrike "(45)" and insert "(44)".

    On page 3, delete lines 18 to 24, inclusive, and insert:

"

            (46)(45)     5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

            (47)    5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;

            (48)    5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;

            (49)    1-Butyl-3-(1-naphthoyl)indole;

            (46)    Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed as a controlled substance in another schedule, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, and salts of isomers and homologues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, and salts of isomers and homologues is possible within the specific chemical designation:

            (a)    Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, or

2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

                Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 1-pentyl-3-(1-naphthoyl)indole (AM-678); 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212;

            (b)    Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

            (c)    Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

                Some trade or other names: 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8); 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203);

            (d)    Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

                Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4);

            (e)    Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

                Some trade or other names: JWH-307;

            (f)    Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;

            (g)    Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent.

                Some trade or other names: 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes C8); cannabicyclohexanol;

            (h)    (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: HU-210;

            (i)    2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone. Some trade or other names: WIN 55, 212-2;

            (47)    6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);

            (48)    2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

            (49)    2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

            (50)    2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

            (51)    2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

            (52)    2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

            (53)    2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

            (54)    2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

            (55)    2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); and

            (56)    2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)".

    On page 4, delete lines 1 to 5, inclusive, and insert:

"

            (50)    1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole; and

            (51)    1-Pentyl-3-(1-naphthoyl)indole.".

    On page 7, delete line 20, and insert:
"
            (46)    Ezogabine,[N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester],".


Moved by:    Kraus
Second by:    Krebs
Action:    Prevailed by voice vote.

MOTION:    DO PASS SB 23 AS AMENDED

Moved by:    Krebs
Second by:    Kraus
Action:    Prevailed by roll call vote. (6-1-0-0)

Voting Yes:    Bradford, Holien, Krebs, Schlekeway, Kraus, Hunhoff (Jean)

Voting No:    Rampelberg

MOTION:    ADJOURN

Moved by:    Krebs
Second by:    Schlekeway
Action:    Prevailed by voice vote.

Cindy Louder
____________________________

Committee Secretary
Jean M. Hunhoff, Chair

../01251000.SHE
Page 1